An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma
In patients with mRCC, a splenic volume increase ≥ 10% at a median of 2.8 months following ICI initiation is independently associated with worse survival compared to an < 10% increase. Monitoring splenic volume changes may serve as a cost-effective radiographic prognostic marker to guide treatment sequencing.
Authors
- S. Patel
- Viraj A. Master (ORCID: https://orcid.org/0000-0002-7251-142X)
- Shreyas Joshi (ORCID: https://orcid.org/0000-0002-0020-5298)
- Taylor Goodstein (ORCID: https://orcid.org/0000-0001-5062-5461)
- S. Nawaz Ahmed
- Bradley Curtis Carthon
- Ö. K. Küçük
- Dattatraya Patil (ORCID: https://orcid.org/0000-0002-8242-9825)
- Haydn Kissick (ORCID: https://orcid.org/0000-0001-7624-5598)
- Vivek Narayan (ORCID: https://orcid.org/0000-0002-8205-738X)
- Bassel Nazha (ORCID: https://orcid.org/0000-0001-6385-1329)
- Jordan Ciuro (ORCID: https://orcid.org/0000-0002-0524-8035)
- Gregory Palmateer
- M N Bilen
- Jacqueline T Brown
- Ahmet Yildirim
- Kenneth Ogan
Institutions
- Emory University (US)
- Piedmont Cancer Institute (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-01-03
- DOI
- https://doi.org/10.1093/oncolo/oyaf397
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00